Antiparkinsonian activity of a single oral dose of PHNO

Mov Disord. 1987;2(1):47-51. doi: 10.1002/mds.870020106.

Abstract

PHNO, a new D-2 agonist, was investigated in five patients with Parkinson's disease. In an acute, open, oral, dose-ranging study comparing benefit from single doses, 4 mg of PHNO was found to be equivalent to one tablet of Sinemet 25/250 mg. Adverse reactions were those anticipated for a dopaminomimetic agent. Because of its novel structure and apparent transcutaneous penetration, further studies on PHNO are desirable.

Publication types

  • Comparative Study

MeSH terms

  • Administration, Oral
  • Adult
  • Aged
  • Carbidopa / administration & dosage
  • Carbidopa / therapeutic use
  • Dopamine Agents / administration & dosage
  • Dopamine Agents / adverse effects
  • Dopamine Agents / therapeutic use*
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Combinations
  • Female
  • Humans
  • Levodopa / administration & dosage
  • Levodopa / therapeutic use
  • Male
  • Middle Aged
  • Oxazines / administration & dosage
  • Oxazines / adverse effects
  • Oxazines / therapeutic use*
  • Parkinson Disease, Secondary / chemically induced
  • Parkinson Disease, Secondary / drug therapy*
  • Parkinson Disease, Secondary / pathology
  • Reaction Time

Substances

  • Dopamine Agents
  • Drug Combinations
  • Oxazines
  • carbidopa, levodopa drug combination
  • naxagolide
  • Levodopa
  • Carbidopa